Hungary Pharmaceuticals & Healthcare Q4 2018
Hungary's underfunded healthcare system will undermine the performance of the pharmaceutical sector over ourforecast period. Poor policy has resulted in pharmaceutical prices rising significantly above EU averages, placing pressure on thepublic healthcare budget. The burden of medicine costs is likely to continue to shift onto household, reducing their affordability andtherefore dampening medicine demand. Unless the Hungarian government makes radical changes to financing the healthcaresystem, multinational pharmaceutical firms will face minimal growth opportunities in the coming years.